A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

Trial Profile

A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Doxorubicin liposomal; Paclitaxel
  • Indications Advanced breast cancer; Early breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2015 Results of sub-group analysis (n=465) presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 03 Jun 2014 Final results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top